glp-1 intracranial hypertension Glucagon-like peptide-1 medicines in neurological and psychiatric disorders Recurrent Idiopathic Intracranial Hypertension–Related Papilledema

Wickens M, Bernstein DS, Kimble J, Parker R (2002) A PUF family portrait: 3UTR regulation as a way of life

The peptide binds by a two-domain mechanism, with its C-terminus held by the extracellular domain while its N-terminus inserts into the transmembrane bundle to switch the receptor on

This condition commonly affects people with metabolic conditions, including obesity, high blood pressure, and type 2 diabetes

First week strategies The first week on semaglutide or the initial tirzepatide dose is when side effects are most likely to appear

Evidence was organized thematically into pharmacokinetics and discontinuation timing, safety of GLP-1 RA exposure in pregnancy, alternative metabolic management strategies, and ethical/clinical considerations

You typically start at 2.5 mg weekly and move up to 5 mg, 10 mg, or 15 mg weekly, depending on your response to the medication and tolerance of side effects